Fig. 2: Antipsychotic effects on P11-KO mice in MK-801 -induced PPI disruption paradigm.
From: A molecular mechanism mediating clozapine-enhanced sensorimotor gating
A Schematic representation of PPI experimental design. B Bar graph showing PPI after treatment with MK-801 (0.3 mg/kg) alone or in combination with clozapine (3 mg/kg) or haloperidol (0.5 mg/kg) in WT mice (two-way rmANOVA, Prepulse: F(2,16) = 66.82, p < 0.001; Treatment: F(3,24) = 21.44, p < 0.001; post-hoc treatment comparisons **p < 0.01, ***p < 0.001, Tukey’s test). C Bar graph showing PPI after treatment with MK-801 (0.3 mg/kg) alone or in combination with clozapine (3 mg/kg) or haloperidol (0.5 mg/kg) in p11-KO mice (two-way rmANOVA, Prepulse: F(2,10) = 17.74, p < 0.001; Treatment: F(3,15) = 5.37, p = 0.01; Prepulse × Treatment: F(6,30) = 2.89, p = 0.024; post-hoc treatment comparisons *p < 0.05, **p < 0.01, ***p < 0.001; Tukey’s test). D Mean PPI across all prepulse intensities in WT and p11-KO mice (two-way rmANOVA, Treatment: F(3,39) = 19.8, p < 0.001; post-hoc treatment comparisons **p < 0.01, ***p < 0.001; Tukey’s test). E Bar graph showing pulse-alone startle amplitude (two-way rmANOVA, Treatment: F(3,39) = 3.2, p = 0.034; Genotype: F(1,13) = 6.76, p = 0.022; post hoc treatment comparisons **p < 0.01; WT vs. p11-KO #p < 0.05, ##p < 0.01; Tukey’s test). WT mice n = 9 (males n = 4, females n = 5), p11-KO n = 6 (females n = 6). Data are presented as mean ± SEM. Veh vehicle, AP antipsychotic, AU arbitrary units, PPI prepulse inhibition, MK MK-801, Hal haloperidol, Ris risperidone, Clz clozapine.
